Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

US life sciences damages averaged $33.5m between 2019-2025
Regulation & Industry
US life sciences damages averaged $33.5m between 2019-2025
Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.   18 June 2026
Court upholds $83m sequencing verdict and sets royalty rate
Americas
Court upholds $83m sequencing verdict and sets royalty rate
A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.   17 June 2026
Amgen and subsidiary dealt $20m blow over rodent antibody tech
Americas
Amgen and subsidiary dealt $20m blow over rodent antibody tech
Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.   15 June 2026
Americas
Moderna: BioNTech is claiming work ‘it never did’
In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.   12 June 2026
Europe
Siemens ordered to recall mammography device across European countries
The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.   11 June 2026
Americas
US biotech fires trade secrets suit at Chinese pharma group
Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.   10 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.   9 June 2026
Careers
Ex-Kirkland patent litigator jumps to rival firm
Known for his work on major pharmaceutical patent disputes and landmark SEP cases, the London-based litigator has joined a new firm as partner.   8 June 2026
Americas
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.   4 June 2026
Biotech
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.   4 June 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.